Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q9BX79

UPID:
STRA6_HUMAN

ALTERNATIVE NAMES:
Retinol-binding protein receptor STRA6; Stimulated by retinoic acid gene 6 protein homolog

ALTERNATIVE UPACC:
Q9BX79; A8K7F1; B7Z5M9; B7Z862; D3DW54; F5GYI8; I3L1G8; Q6PJF8; Q71RB9; Q7L9G1; Q7Z3U9; Q8TB21; Q9BX78; Q9H9U8

BACKGROUND:
The Stimulated by retinoic acid gene 6 protein homolog, or STRA6, functions as a critical retinol transporter. It accepts and transfers retinol to facilitate its cellular uptake, playing a key role in the activation of signaling cascades that influence cellular responses to insulin and the homeostasis of vitamin A. Particularly crucial in the eye, STRA6's function is vital under vitamin A deficiency conditions.

THERAPEUTIC SIGNIFICANCE:
Given STRA6's involvement in Microphthalmia, syndromic, 9, a rare disease marked by anophthalmia or severe microphthalmia and pulmonary hypoplasia, its study offers promising avenues for therapeutic intervention. Understanding the role of STRA6 could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.